COVID-19: Developing a large-scale synthesis of a drug potentially curing COVID-19 for the Canadian manufacturing industry

最近爆发的2019年冠状病毒传染病(新冠肺炎)引起了全世界的担忧，并引发了史无前例的恐慌，因为这一全球大流行继续导致死亡，截至2020年4月14日，全球有近200万确诊病例和超过12万确诊死亡。随之而来的是，数以百万计的人的生活正受到强制隔离/隔离的影响，世界各地的卫生系统正在不堪重负，全球经济因新冠肺炎爆发的涟漪效应而受损。 羟基氯喹是一种广泛使用的抗疟疾和自身免疫性疾病的药物，最近被确定为一种潜在的广谱抗病毒药物，有望治疗新冠肺炎。重要的是，羟氯喹是一种被证明是安全的药物，使用了70多年，因此简化了它与新冠肺炎的临床使用。虽然羟基氯喹的治疗潜力是有希望的，但这种药物在加拿大的现有供应链是有限的；因此，出现了真正的供需瓶颈。考虑到越来越多的边境关闭不可避免地会导致离岸毒品进口成本的增加，这一点尤其相关。 拟议中的与Biolyse制药公司的合作涉及开发一种可靠的公斤级合成羟氯喹，这是一种潜在的广谱抗病毒药物，有望治疗新冠肺炎。通过这样做，该公司的合作伙伴将把自己定位在战略位置，从新冠肺炎提供一种低成本、容易获得的拯救(加拿大)生命的药物，同时从经济上受益并促进加拿大的制药生产。同时，最重要的是，这项事业将为加拿大提供治疗新冠肺炎感染患者的资源。

The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and evoked a scare of epic proportion as this global pandemic continues to causes deaths with nearly two million confirmed cases and over 120,000 confirmed deaths worldwide as of April 14, 2020. With this untold millions of people's lives are being affected as a result of mandatory isolations/quarantines and worldwide health systems are being overwhelmed and the global economy damaged as a ripple effect of the COVID-19 outbreak. Repurposing of hydroxychloroquine, a widely used anti-malarial and autoimmune disease drug, was recently identified as a potential broad-spectrum antiviral drug, with promise in treating COVID-19. Importantly, hydroxychloroquine is a proven safe drug used for more than 70 years and, thus, streamlining it clinical use against COVID-19. While the therapeutic potential of hydroxychloroquine is promising, the existing supply chain of this drug in Canada is limited; thus, presenting a real supply and demand bottleneck. This is especially pertinent given mounting border closures that inevitably will lead to increasing cost of offshore drug imports. The proposed partnership with Biolyse Pharma Cooperation involves the development of a reliable Kilogram-scale synthesis of hydroxychloroquine, a potential broad-spectrum antiviral drug, with promise in treating COVID-19. In doing so, the company partner will position themselves at a strategic place for offering a low-cost, readily available drug for saving (Canadian) lives from COVID-19, while benefiting economically and fostering Canadian based Pharma production. At the same time, most importantly this undertaking will provide Canada with a resource to treat COVID-19 infected patients.